Notify me when L.P. Versant Vantage II files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| TPST | Tempest Therapeutics, Inc. | Common Stock, par value $0.001 per share | 3.7% | $1,108,210 | -$13,298,570 | 162,972 | -92% | Versant Vantage II, L.P. | 11 Aug 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|